Author:
Di Bello Francesco,Jannello Letizia Maria Ippolita,Siech Carolin,de Angelis Mario,Rodriguez Peñaranda Natali,Tian Zhe,Goyal Jordan A.,Ruvolo Claudia Collà,Califano Gianluigi,Creta Massimiliano,Morra Simone,Saad Fred,Shariat Shahrokh F.,de Cobelli Ottavio,Briganti Alberto,Chun Felix K. H.,Puliatti Stefano,Longo Nicola,Karakiewicz Pierre I.
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268–77.
2. Luo Y, Feng B, Wei D, Han Y, Li M, Zhao J, et al. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity. Sci Rep. 2020;10:17674.
3. Uroweb - European Association of Urology. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: Introduction – Uroweb [cited 28 Sep 2022]. Available at: https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma
4. Di Bello F, Jannello L, Siech C, et al. Adjuvant systemic therapy improved survival after radical nephroureterectomy for upper tract urothelial carcinoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15814-8.
5. Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol. 2017;35(8):852–60.